CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Osteologix Holdings PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Osteologix Holdings PLC
3rd Floor, Europa House, Harcourt Centre
Harcourt Street, Dublin 2
Phone: +353 14161290p:+353 14161290 DUBLIN, 23060  Ireland Ticker: OLGX OLGX
This company ceased filing statements with the SEC on 1/4/2011.
This company is no longer actively traded on any major stock exchange.
Business Summary
Osteologix Holdings Plc. is engaged in developing pharmaceuticals for the treatment and prevention of diseases of bone and joint tissues. The Company is focused on its candidate drug programs in the areas of metabolic bone diseases and arthritis. Its lead product candidate, NB S101, is a dual acting bone agent, for the treatment of osteoporosis. NB S101 decreases resorption of bone while maintaining or increasing formation of new bone. It has completed a preclinical program demonstrating the pharmacodynamic effects of NB S101, as well as documenting its safety and toxicological properties. In preclinical models of osteoporosis, NB S101 has demonstrated effects on both reducing bone resorption and increasing bone formation and bone mineralization. Other clinical areas for which NB S101 is being investigated consist of disorders, such as osteoarthritis, metastatic bone disease, hyperparathyroidism-associated bone disease, secondary osteoporosis and renal disease.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201012/31/2009YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
5960 Nonstore retailers
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board John M.Barberich 57 12/29/2009 12/29/2009
President, Chief Executive Officer, Director Philip J.Young 6/7/2007 5/1/2007
Director KlausEldrup-Jorgensen 51 12/29/2009 5/1/2003

Business Names
Business Name
OLGX
OLGXF
Osteologix ApS

General Information
Number of Employees: 3 (As of 12/31/2009)
Outstanding Shares: 32,970,871 (As of 11/15/2010)
Shareholders: 31
Stock Exchange: OTC
Federal Tax Id: 320104570


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023